… practice to fight the novel coronavirus disease (COVID-19), and … candidate drugs to treat
COVID-19, Janus Kinase (JAK) … remdesivir for the treatment of COVID-19 in hospitalized patients …

… route of Covid-19 [Citation18]. These properties may offer clinical benefit in preventing the
deterioration of coronavirus disease 2019 (Covid-19) and reducing the death toll from Covid-…

… factors for disease worsening and death associated with Covid-19 … disease-associated
interstitial lung disease. Anti-MDA5 antibody-positive interstitial lung diseases, which, like Covid-…

… but the risk of Janus kinase inhibitor (JAKi) treatment has not been addressed. In light of
the growing off-label use of JAKis in dermatology in addition to pharmaceutical industry-…

… of Janus kinase (JAK) inhibitors in the time of severe acute respiratory syndrome coronavirus
2 (… However, data in the literature regarding the possible use of JAK inhibitors in COVID 19 …

… ill COVID-19 patients show genetic polymorphisms in one IFN receptor gene (IFNRA2) and
in a gene locus near the Janus kinase (… understanding on COVID-19 disease and therapeutic …

… Janus kinase (JAK) inhibitors for the treatment of hospitalised patients with COVID-19 have
been extensively studied. Initially, at the start of the pandemic outside of China, baricitinib …

… We would like to report our results in COVID-19 patients with … The median time from the onset
of COVID-19-related … stable disease, and 2/18 patients showed progressive disease. At day …

… Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and has become the biggest threat to global public health since …

… The disease has been designated COVID-19, an acronym for “coronavirus disease 2019”.
To date, efficacy of antiviral drugs explored in COVID-19 awaits confirmation [2, 3]. …